AOD-9604: The Complete Research Guide

There's a reason AOD-9604 keeps showing up in longevity and metabolic research circles. It promises something that sounds almost too good to be true: the fat-burning benefits of human growth hormone without the insulin resistance, edema, or growth effects that make HGH problematic for long-term use.

But does the research back it up? Let's dig into what we actually know.

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH), specifically amino acids 177-191 from the C-terminal region. That's the tail end of the HGH molecule - the part researchers identified as responsible for HGH's lipolytic (fat-burning) activity.

The key modification: a tyrosine residue is added at position 177, creating a more stable and active peptide. This isn't just a broken piece of HGH - it's an engineered variant designed to isolate one specific function.

AOD-9604 was originally developed by Professor Frank Ng at Monash University in Australia during the 1990s, and it's been through more rigorous clinical investigation than most research peptides on the market.

How AOD-9604 Works: Mechanism of Action

Understanding AOD-9604 requires understanding how HGH handles fat metabolism - and why the full hormone is overkill for that purpose.

The Lipolytic Pathway

HGH stimulates fat breakdown through a specific signaling cascade. AOD-9604 mimics this pathway by:

1. Stimulating lipolysis - the breakdown of triglycerides stored in adipose (fat) tissue into free fatty acids and glycerol
2. Inhibiting lipogenesis - the process by which the body converts non-fat food sources into stored fat
3. Activating beta-3 adrenergic receptors - these receptors, found primarily on fat cells, trigger the release of stored fatty acids when activated

The dual action - breaking down existing fat while preventing new fat storage - is what makes AOD-9604 particularly interesting compared to compounds that only do one or the other.

What It Doesn't Do (And Why That Matters)

Here's the critical distinction: AOD-9604 does not activate the growth hormone receptor in the same way full HGH does. That means:

• No IGF-1 elevation - Full HGH spikes insulin-like growth factor 1, which drives cell proliferation (a concern for cancer risk with long-term use). AOD-9604 doesn't do this.
• No insulin resistance - HGH is notorious for impairing glucose metabolism. AOD-9604 has shown no effect on blood glucose or insulin sensitivity in clinical trials.
• No acromegalic effects - No bone growth, no organ enlargement, no carpal tunnel. The growth-promoting properties of HGH live in a different region of the molecule.
• No water retention - The bloating and edema common with HGH don't appear with AOD-9604.

This selectivity is the entire value proposition. You get the metabolic effect without the systemic disruption.

What Does the Research Show?

AOD-9604 has a more substantial clinical research base than most peptides in the research market. Here's what stands out:

Fat Metabolism Studies

The foundational research comes from Monash University. In obese Zucker rats (a standard model for metabolic research), AOD-9604 produced significant reductions in body fat without affecting food intake, growth rate, or lean mass. The fat loss was selective - it preferentially targeted visceral and subcutaneous adipose tissue.

A 2001 study published in the Journal of Endocrinology showed that AOD-9604 stimulated lipolysis in both human and murine adipose tissue at concentrations as low as 10 nanomolar. Importantly, the anti-lipogenic effect was confirmed independently of the lipolytic activity - meaning it works on both sides of the fat storage equation simultaneously.

Human Clinical Trials

AOD-9604 made it to Phase 2b clinical trials for obesity - further than most research peptides ever get. The trials, conducted by Metabolic Pharmaceuticals Limited:

• Phase 1 - Safety established. No serious adverse events. No effect on IGF-1 or glucose levels.
• Phase 2a - Dose-ranging study showed statistically significant fat loss compared to placebo over 12 weeks.
• Phase 2b - Larger trial (300+ participants). Results were mixed - the primary endpoint wasn't met in the intention-to-treat analysis, but subgroup analyses showed significant effects at specific doses, particularly in participants with higher baseline BMI.

The Phase 2b results led to the program being shelved for obesity as a standalone indication. But researchers have noted methodological concerns with the trial design that may have masked real effects - including a high placebo response rate and short duration.

Cartilage and Joint Research

This is where AOD-9604 research has taken an interesting turn. Studies have shown that AOD-9604 stimulates proteoglycan and collagen synthesis in cartilage cells. A 2020 study demonstrated that intra-articular injection of AOD-9604 significantly improved cartilage repair in an animal model of osteoarthritis.

The TGA (Australia's Therapeutic Goods Administration) approved AOD-9604 as a food substance in 2010, and it's been investigated for joint health applications. Some Australian clinics have been using it in combination with hyaluronic acid for knee osteoarthritis.

This dual application - metabolic and musculoskeletal - makes AOD-9604 unusually versatile among research peptides.

AOD-9604 vs HGH Fragment 176-191

You'll see these two discussed interchangeably, but they're not identical:

The tyrosine modification in AOD-9604 isn't cosmetic - it meaningfully changes the peptide's pharmacological profile. If you're comparing the two for research purposes, AOD-9604 has substantially more published data behind it.

Dosing Ranges in Published Literature

The following ranges are reported in peer-reviewed studies and clinical trial protocols. This is not guidance or recommendation - researchers should consult the primary literature for their specific applications.

Subcutaneous Administration (per published studies)

• Ranges reported: 250-500 mcg per administration
• Frequency in trials: Once daily, fasted state
• Study durations: 12-24 weeks
• Note: Morning administration was used in most published protocols

Intra-Articular Applications (per published studies)

• Ranges reported: 50-200 mcg per administration
• Frequency in studies: Weekly or biweekly
• Study durations: 4-6 weeks in published protocols

Reconstitution

AOD-9604 is typically supplied as a lyophilized powder. Standard reconstitution with bacteriostatic water. The peptide is relatively stable once reconstituted - refrigerated storage at 2-8°C. See our reconstitution guide for detailed instructions.

Storage and Handling

AOD-9604 is more stable than many peptides, but still requires proper handling:

• Lyophilized: Room temperature is acceptable for short-term storage, but refrigeration extends shelf life significantly
• Reconstituted: Refrigerate at 2-8°C, use within 4-6 weeks
• Light sensitivity: Moderate - store in original vial, avoid direct sunlight
• Freeze-thaw: Avoid repeated freeze-thaw cycles

For a deep dive on proper peptide storage, check our storage guide.

Side Effects and Safety Profile

One of AOD-9604's strongest selling points is its safety data:

Observed in Clinical Trials

• Injection site reactions - mild redness or irritation (most common, transient)
• Headache - reported at similar rates to placebo
• No significant adverse events across Phase 1 and Phase 2 trials

What Wasn't Observed

• No changes in blood glucose or HbA1c
• No changes in IGF-1 levels
• No effects on thyroid function
• No cardiovascular effects
• No changes in hematology or liver/kidney function markers

The TGA's 2010 classification of AOD-9604 as a food substance speaks to its safety profile - that's a regulatory bar most peptides will never clear.

Who's Researching AOD-9604?

Interest in AOD-9604 spans several research domains:

• Metabolic researchers - investigating targeted fat reduction without hormonal disruption
• Orthopedic/sports medicine - exploring cartilage repair and joint regeneration
• Longevity researchers - interested in metabolic optimization without the risks of full HGH replacement
• Lipedema researchers - investigating whether AOD-9604's selective lipolysis could help with this poorly understood condition

Quality Considerations

AOD-9604 is widely available, but quality varies dramatically. Key things for researchers to verify:

• Certificate of Analysis (COA) - should show average 99.7% purity via HPLC. Learn how to read one in our COA guide.
• Mass spectrometry data - confirms correct molecular weight (1817.12 Da for the free acid form)
• Endotoxin testing - especially important for injectable research applications
• Source verification - ensure the supplier manufactures or sources from GMP-compliant facilities

The Bottom Line

AOD-9604 occupies a unique position in the peptide research landscape. It has more human clinical data than most research peptides, a clean safety profile, and a mechanism of action that's well-characterized at the molecular level. The cartilage repair angle adds a second dimension that most fat-loss compounds don't offer.

The Phase 2b trial results were disappointing for the pharmaceutical development pathway, but the underlying science remains solid. For researchers interested in targeted lipolysis without growth hormone's systemic effects, AOD-9604 remains one of the most compelling compounds to study.

Whether the focus is metabolic optimization, joint health, or understanding how growth hormone fragments interact with adipose tissue, AOD-9604 gives researchers a lot to work with.

This article is for educational and research purposes only. AOD-9604 is sold as a research compound and is not approved for human therapeutic use in most jurisdictions. Always ensure compliance with local regulations when purchasing research peptides.

Looking for high-purity AOD-9604 with verified COAs? Browse our research peptide catalog for third-party tested compounds.

Related Reading:

• Tirzepatide Complete Guide - the dual GIP/GLP-1 agonist often studied alongside AOD-9604
• Semaglutide Complete Guide - another key metabolic peptide via GLP-1 receptor agonism
• BPC-157 Complete Guide
• Best Research Peptides in 2026